JPRN-jRCT2030230343招募中1 期
Open-label dose-finding trial to explore safety, pharmacokinetics, pharmacodynamics, and efficacy of BI 3706674 given orally as monotherapy in patients with unresectable metastatic KRAS wild type amplified gastric, oesophageal, and gastroesophageal-juncti
akahara Asuka0 个研究点目标入组 15 人开始时间: 2023年9月12日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
入选标准
- •Patients with pathologically confirmed diagnosis of locally advanced or metastatic GAC, EAC, and GEJAC with KRAS wt amplification and documented disease progression despite at least 1 line of prior therapy
- •Dose escalation part only: Patients with advanced or metastatic relapsed or refractory solid tumours of any histology with KRAS wt amplification or harbouring a KRAS G12V mutation who have exhausted treatment options known to prolong survival for their disease.
- •- At least one target lesion that can be measured per RECIST version 1.1 (radiated lesions do not qualify as target lesions unless there has been demonstrated progression of the lesion after completion of radiotherapy)
- •Dose escalation part only: Patients with no lesions measurable per RECIST version 1.1 may be included if agreed between sponsor and investigator.
- •- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- •- Dose confirmation part only: Willingness to undergo pre- and on-treatment tumour biopsies
- •- Adequate organ function as defined in Section 3.3.2.
- •- All toxicities related to previous anti-cancer therapies have resolved to <= CTCAE Grade 1 prior to trial treatment administration (except for alopecia and peripheral neuropathy which must be <= CTCAE Grade 2 and amenorrhea or menstrual disorders which can be any grade)
排除标准
- •- Previous anti-cancer chemotherapy within 3 weeks of the first administration of trial drug
- •- Previous anti-cancer hormonal treatment or anti-cancer immunotherapy within 2 weeks of the first administration of trial drug
- •- Previous treatment with RAS, MAPK or SOS1 targeting agents
研究者
相似试验
尚未招募
1 期
A study to test how well different doses of BI 3706674 are tolerated by people with advanced cancer in the stomach and oesophagusGAC, EAC, and GEJAC solid tumours harbouring a KRAS wt amplification Solid tumours of any histologyGAC, EAC, and GEJAC solid tumours harbouring a KRAS wt amplificationJPRN-jRCT2030230282Kurei Katsutoshi146
进行中（未招募）
1 期
A study in people with cystic fibrosis who have a fungal lung infection, looking at the safety of inhaled PC945, it's effect on the body and how the body affects the drug.EUCTR2018-000243-87-GBPulmocide Ltd18
未知
1 期
Open-label study to assess safety, pharmacokinetics and exposed dose of NMK20 in healthy Japanese male subjectsHealthy Japanese male subjectsJPRN-jRCT2080222333ihon Medi-Physics Co., Ltd.6
已完成
1 期
A phase I study to evaluate the safety and pharmacokinetics of ONX 0801 in advanced solid tumoursAdvanced solid tumoursMalignant neoplasm of other and ill-defined sitesCancerISRCTN79302332Onyx Pharmaceuticals (USA)60
尚未招募
4 期
To evaluate the effect of PentaSure fibersupplementation in the management of Functional Constipation among ChildreCTRI/2023/10/058430Hexagon Nutrition Limited